Analytical Data
-
Gene name
U100
- Application
-
Alternative Names
Glycoprotein 105 Glycoprotein Q-80k HCLF1 protein
-
Species
Human herpesvirus 6B
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9QJ11
-
Expression Region
25-354aa
-
Molecular Weight
44.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The U100 recombinant protein has garnered significant attention in recent years due to its potential applications in biotechnology and medicine. Research surrounding this protein has been motivated by the increasing need for effective therapeutics and innovative solutions to tackle various diseases. U100, a fusion protein derived from a unique set of genetic sequences, exhibits specific biochemical properties that make it a valuable candidate for therapeutic interventions. Studies have indicated that its structural integrity and functionality can be finely tuned through recombinant DNA technology, allowing for large-scale production and purification. The protein's mechanism of action, as it interacts with cellular pathways, holds promise in drug development, particularly in targeting cancer cells and modulating immune responses. Additionally, U100 has potential implications in the field of vaccine development, as its ability to elicit robust immune responses could enhance the effectiveness of traditional vaccines. The ongoing research aims to further elucidate its biological activities and optimize its efficacy, paving the way for clinical applications. Overall, the U100 recombinant protein represents a significant advancement in the field of molecular biology and therapeutic development, reflecting the intersection of genetic engineering and disease management.
